Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Oncoimmunology

• Publication date

  2017-03-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1080/2162402X.2017.1295903PMID 28507806PMCID PMC5414887
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints.

  2017influential reference
• Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma

  2017cited by this paper
• Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy

  2017influential reference
• The movers and shapers in immune privilege of the CNS

  2017cited by this paper
• The “cancer immunogram”

  2016cited by this paper
• Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.

  2016cited by this paper
• Mutational Landscape and Sensitivity to Immune Checkpoint Blockers

  2016influential reference
• Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation

  2016cited by this paper
• Immunovirotherapy with measles virus strains in combination with anti–PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment

  2016cited by this paper
• Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM

  2016cited by this paper
• Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

  2016cited by this paper
• Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas

  2016cited by this paper
• Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.

  2016cited by this paper
• Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade

  2016influential reference
• PD-1 blockade enhances the vaccination-induced immune response in glioma.

  2016cited by this paper
• Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

  2016cited by this paper
• In Vitro Generation of Murine Dendritic Cells for Cancer Immunotherapy: An Optimized Protocol.

  2016cited by this paper
• Therapeutic administration of IL‐15 superagonist complex ALT‐803 leads to long‐term survival and durable antitumor immune response in a murine glioblastoma model

  2016cited by this paper
• Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell–driven rejection of high-grade glioma

  2016cited by this paper
• Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysis

  2016cited by this paper
• Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM).

  2016cited by this paper
• Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.

  2016cited by this paper
• Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

  2016cited by this paper
• Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach

  2016cited by this paper
• Prospects of immune checkpoint modulators in the treatment of glioblastoma

  2015influential reference
• Active dendritic cell immunotherapy for glioblastoma: Current status and challenges

  2015cited by this paper
• Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer

  2015cited by this paper
• Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

  2015cited by this paper
• The future of immune checkpoint therapy

  2015influential reference
• Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

  2015cited by this paper
• Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal

  2015cited by this paper
• Neoantigens in cancer immunotherapy

  2015cited by this paper
• Newcastle disease virotherapy induces long‐term survival and tumor‐specific immune memory in orthotopic glioma through the induction of immunogenic cell death

  2015cited by this paper
• Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma

  2015cited by this paper
• Pembrolizumab versus Ipilimumab in Advanced Melanoma.

  2015cited by this paper
• Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

  2015cited by this paper
• Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers

  2015cited by this paper
• Checkpoint blocking antibodies in cancer immunotherapy

  2014cited by this paper
• Glioma‐derived galectin‐1 regulates innate and adaptive antitumor immunity

  2014cited by this paper
• Integration of mRNA Expression Profile, Copy Number Alterations, and microRNA Expression Levels in Breast Cancer to Improve Grade Definition

  2014cited by this paper
• Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

  2014cited by this paper
• Clinical use of dendritic cells for cancer therapy.

  2014cited by this paper
• The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma

  2014cited by this paper
• PROGgeneV2: enhancements on the existing database

  2014cited by this paper
• Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model

  2014cited by this paper
• The Cancer Genome Atlas Pan-Cancer analysis project

  2013cited by this paper
• The somatic genomic landscape of glioblastoma.

  2013cited by this paper
• Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection

  2013cited by this paper
• Foxp3+ regulatory T cells are activated in spite of B7‐CD28 and CD40‐CD40L blockade

  2013cited by this paper
• Determination of genomic copy number alteration emphasizing a restriction site-based strategy of genome re-sequencing

  2013cited by this paper
• Signatures of mutational processes in human cancer

  2013cited by this paper
• Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.

  2013cited by this paper
• Danger signalling during cancer cell death: origins, plasticity and regulation

  2013cited by this paper
• Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.

  2013cited by this paper
• Sequential Immunotherapy by Vaccination With GM-CSF–expressing Glioma Cells and CTLA-4 Blockade Effectively Treats Established Murine Intracranial Tumors

  2012cited by this paper
• The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012influential reference
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Rembrandt: Helping Personalized Medicine Become a Reality through Integrative Translational Research

  2009cited by this paper
• DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.

  2009cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function

  2007cited by this paper
• Java Treeview - extensible visualization of microarray data

  2004influential reference
• Open source clustering software.

  2004cited by this paper
• Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors

  2002cited by this paper

• Dendritic cell vaccines: Current research progress, challenges, and opportunities

  2025cites this paper
• Glioma tumor microenvironment and immunotherapy: past, present, and future

  2025cites this paper
• Advancing Glioblastoma Therapy: Learning From the Past and Innovations for the Future.

  2025cites this paper
• Gut microbiota and their influence in brain cancer milieu

  2025cites this paper
• Going viral: targeting glioblastoma using oncolytic viruses

  2025cites this paper
• Promising Cancer Vaccine for Glioblastoma Therapy: A Focus on mRNA Vaccine

  2025cites this paper
• In situ administration of STING-activating hyaluronic acid conjugate primes anti-glioblastoma immune response

  2024cites this paper
• Insights into the glioblastoma tumor microenvironment: current and emerging therapeutic approaches

  2024cites this paper
• A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives

  2024cites this paper
• Establishment and immune phenotyping of patient-derived glioblastoma models in humanized mice

  2024cites this paper
• Glioblastoma and Immune Checkpoint Inhibitors: A Glance at Available Treatment Options and Future Directions

  2024cites this paper
• In Vivo Mouse Models for Adult Brain Tumors: Exploring Tumorigenesis and Advancing Immunotherapy Development.

  2024cites this paper
• Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade

  2024cites this paper
• Elevated HSPB1 Expression Is Associated with a Poor Prognosis in Glioblastoma Multiforme Patients

  2023cites this paper
• Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired

  2023cites this paper
• Nucleic acid immunotherapeutics and vaccines: a promising approach to glioblastoma multiforme treatment.

  2023cites this paper
• The Role of Antibody-Based Therapies in Neuro-Oncology

  2023cites this paper
• LAIR1 drives glioma progression by nuclear focal adhesion kinase dependent expressions of cyclin D1 and immunosuppressive chemokines/cytokines

  2023cites this paper
• NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma

  2023cites this paper
• γδ T Cells in Brain Homeostasis and Diseases

  2022cites this paper
• Cancer cell intrinsic TIM-3 induces glioblastoma progression

  2022cites this paper
• The Oncogenesis of Glial Cells in Diffuse Gliomas and Clinical Opportunities

  2022cites this paper
• Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma

  2022cites this paper
• Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization

  2022cites this paper
• Combination of DNA Vaccine and Immune Checkpoint Blockades Improves the Immune Response in an Orthotopic Unresectable Glioblastoma Model

  2022cites this paper
• Current Immunotherapeutic Strategies for the Treatment of Glioblastoma

  2021cites this paper
• Immunogenomic, single-cell and spatial dissection of CD8+T cell exhaustion reveals critical determinants of cancer immunotherapy

  2021cites this paper
• Иммунология и перспективы иммунотерапии злокачественных глиом: использование факторов гуморального иммунитета Immunology and prospects of immunotherapy against malignant gliomas: humoral immunity

  2021cites this paper
• Efficacy and Safety of Actively Personalized Neoantigen Vaccination in the Management of Newly Diagnosed Glioblastoma: A Systematic Review

  2021cites this paper
• Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy

  2021cites this paper
• Loss of TGFβ signaling increases alternative end-joining DNA repair that sensitizes to genotoxic therapies across cancer types

  2021cites this paper
• Analysis of human glioma-associated co-inhibitory immune checkpoints in glioma microenvironment and peripheral blood

  2021cites this paper
• Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches

  2020cites this paper
• Decoding cancer cell death-driven immune cell recruitment: An in vivo method for site-of-vaccination analyses.

  2020cites this paper
• CTLA-4 correlates with immune and clinical characteristics of glioma

  2020cites this paper
• Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology

  2020cites this paper
• Tumor-Specific T Cell Activation in Malignant Brain Tumors

  2020cites this paper
• Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy

  2020cites this paper
• CAR T cells and checkpoint inhibition for the treatment of glioblastoma

  2020cites this paper
• Defective Regulation of Membrane TNFα Expression in Dendritic Cells of Glioblastoma Patients Leads to the Impairment of Cytotoxic Activity against Autologous Tumor Cells

  2020cites this paper
• Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors

  2020cites this paper
• Necroptosis in Immuno-Oncology and Cancer Immunotherapy

  2020cites this paper
• Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma

  2020cites this paper
• Indoleamine 2, 3-Dioxygenase: A Professional Immunomodulator and Its Potential Functions in Immune Related Diseases

  2020cites this paper
• Immunocompetent Mouse Models in the Search for Effective Immunotherapy in Glioblastoma

  2020cites this paper
• Mutational load in carotid body tumor

  2019cites this paper
• Immunity, Hypoxia and Metabolism - the ménage à trois of cancer: implications for immunotherapy.

  2019cites this paper
• Trial watch: dendritic cell vaccination for cancer immunotherapy

  2019cites this paper
• Type I interferons and dendritic cells in cancer immunotherapy.

  2019cites this paper
• PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models

  2019cites this paper
• Type I interferons and endoplasmic reticulum stress in health and disease

  2019cites this paper
• RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma

  2018cites this paper
• The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy

  2018cites this paper
• Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas

  2018cites this paper
• Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)

  2018cites this paper
• Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

  2018cites this paper
• Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models

  2018cites this paper
• Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma

  2018cites this paper
• Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment.

  2018cites this paper
• Immune checkpoint receptors: homeostatic regulators of immunity

  2018cites this paper
• The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis

  2018influential citation
• Defining the role of the tumor vasculature in antitumor immunity and immunotherapy

  2018cites this paper
• Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics

  2017cites this paper
• Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses

  2017cites this paper
• Trial watch: Dendritic cell-based anticancer immunotherapy

  2017cites this paper
• Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape.

  2017influential citation
• MicroRNA in Glioblastoma: An Overview

  2017cites this paper